To achieve this, we developed two in-house clones 1A8 and 4F5 targeting DEFA5 monoclonal antibodies (mAbs), and two U.S. patents that cover the protein compounds, compositions, and mAbs potentially more selective and avid against DEFA5 for exact binding to produce adequate specificity, which only recognizes DEFA5, which is diagnostic for the IBD subtype. Here, DEFA5 is linked to inflammatory bowel disease.